Randomised trial of growth hormone in short normal girls.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

There are few data on the long-term outcome of growth-hormone treatment in short normal children.

The researchers assessed the impact of growth-hormone treatment on pubertal development and near-final height in girls.

Who Took Part

The abstract describes 20 girls taking part.

PubMed indexes the participants as children, women only.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The researchers assessed pubertal staging and height gain every 6 months.

What Was Measured

There are few data on the long-term outcome of growth-hormone treatment in short normal children.

The researchers assessed the impact of growth-hormone treatment on pubertal development and near-final height in girls.

Topics PubMed links to this paper include Body Height, Human Growth Hormone and Puberty.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Lancet (London, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.